Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 146

Sort by

Sort Order Select

Journal Articles

Losing control to bad relatives

Vahid Afshar-Kharghan

Blood (2021) 137 (25): 3462–3463.

https://doi.org/10.1182/blood.2021011364

Published: 2021

Journal Articles

Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases

Héctor Martin Merinero, Marta Subías, Amaia Pereda, Elena Gómez-Rubio, Lucia Juana Lopez, Constantino Fernandez, Elena Goicoechea de Jorge, Sonsoles Martin-Santamaria, Francisco Javier Cañada, Santiago Rodríguez de Córdoba

Blood (2021) 137 (25): 3484–3494.

https://doi.org/10.1182/blood.2020010069

Published: 2021

Includes: Supplemental data

Journal Articles

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

Blood (2021) 137 (18): 2438–2449.

https://doi.org/10.1182/blood.2020009280

Published: 2021

Includes: Supplemental data

Journal Articles

Eculizumab and aHUS: to stop or not

Robert A. Brodsky

Blood (2021) 137 (18): 2419–2420.

https://doi.org/10.1182/blood.2020010234

Published: 2021

Journal Articles

Familial risk of developing atypical hemolytic-uremic syndrome

Emilia Arjona, Ana Huerta, Elena Goicoechea de Jorge, Santiago Rodríguez de Córdoba

Blood (2020) 136 (13): 1558–1561.

https://doi.org/10.1182/blood.2020006931

Published: 2020

Includes: Supplemental data

Journal Articles

Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome in Pregnancy: A Single Center Retrospective Review

Pallavi Kopparthy, MD, Anita Rajasekhar, MD

Blood (2019) 134 (Supplement_1): 4899.

https://doi.org/10.1182/blood-2019-131846

Published: 2019

Journal Articles

Rare Germline Mutations in Complement Regulatory Genes Make the Antiphospholipid Syndrome Catastrophic

Shruti Chaturvedi, MBBS, MS, Evan M Braunstein, MD PhD, Xuan Yuan, MD MSc, Hang Chen, Ravi Kumar Alluri, PhD, Michael B. Streiff, MD, Michelle Petri, MD MPH, Mark Crowther, MD MSc, FRCPC, Keith R McCrae, MD, Robert A. Brodsky, MD

Blood (2019) 134 (Supplement_1): 4.

https://doi.org/10.1182/blood-2019-129115

Published: 2019

Journal Articles

Defibrotide Inhibits Endothelial Cell Injury Induced By Plasmas of Patients with Thrombotic Microangiopathies

Jeffrey Laurence, MD, Sonia Elhadad, PhD

Blood (2019) 134 (Supplement_1): 3676.

https://doi.org/10.1182/blood-2019-124158

Published: 2019

Journal Articles

Relationship between Pharmacokinetics and Antidrug Antibody Status of ABP 959, a Biosimilar Candidate to Eculizumab: Results from a Pharmacokinetic Similarity Study

Vladimir Hanes, MD, Jean Pan, Daniel T. Mytych, PhD, David Chien, MD, Vincent Chow

Blood (2019) 134 (Supplement_1): 3520.

https://doi.org/10.1182/blood-2019-128621

Published: 2019

Journal Articles

Clinical Characteristics of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): A Retrospective Chart Review Study

Vladimir Hanes, MD, Jean Pan, Vincent Chow

Blood (2019) 134 (Supplement_1): 4789.

https://doi.org/10.1182/blood-2019-130409

Published: 2019

Journal Articles

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Luciano J. Costa, MD PhD, Saurabh Chhabra, MD, Kelly N. Godby, MD, Eva Medvedova, MD, Robert F. Cornell, MD MS, Aric C. Hall, MD, Rebecca W. Silbermann, MD, Racquel Innis-Shelton, MD, Binod Dhakal, MBBS, Diego DeIdiaquez, MD, Pamela Hardwick, RN, Yelak Biru, James L. Omel, MD, Parameswaran Hari, MBBS, MD, Natalie Scott Callander, MD

Blood (2019) 134 (Supplement_1): 860.

https://doi.org/10.1182/blood-2019-123170

Published: 2019

Journal Articles

Plasmic and Plasic Αre Εxcellent Predictors of Severe ADAMTS13 Deficiency in Thrombotic Microangiopathy Patients without Secondary Causes

Blood (2019) 134 (Supplement_1): 4913.

https://doi.org/10.1182/blood-2019-125343

Published: 2019

Journal Articles

Monoclonal Gammopathy with Secondary Atypical Hemolytic-Uremic Syndrome

Trisha Kissoon, MD MBA, Sudha Mannemuddhu, MD, Mansi Dalal, MD, Lawrence Shoemaker, MD

Blood (2019) 134 (Supplement_1): 5465.

https://doi.org/10.1182/blood-2019-131826

Published: 2019

Journal Articles

Treatment of Delayed Hemolytic Transfusion Reactions in Sickle Cell Disease Patients By an Anti-C5 Antibody

Blood (2019) 134 (Supplement_1): 2458.

https://doi.org/10.1182/blood-2019-127176

Published: 2019

Journal Articles

Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers

Kishor Devalaraja-Narashimha, PhD DVM, Yan G Ni, PhD, Cong Huang, Ming-Dauh Wang, PhD, Umesh Chaudhari, MD, Srinivasa Prasad, PhD, Olivier Harari, MD PhD, Andrew J Rankin, PhD, Lori Morton, PhD, Jonathan Weyne, MD

Blood (2019) 134 (Supplement_1): 2278.

https://doi.org/10.1182/blood-2019-129865

Published: 2019

Journal Articles

Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab

Spero Cataland, MD, Gema Ariceta, Peter Chen, Bradley Dixon, Katherine Garlo, Laurence Greenbaum, MD PhD, Eric Rondeau, Marie Scully, Stephan Ortiz, RPh, PhD

Blood (2019) 134 (Supplement_1): 1099.

https://doi.org/10.1182/blood-2019-122421

Published: 2019

Journal Articles

Adherence to Infectious Disease Screening and Immunization Guidelines When Treating Non-Malignant Immune-Mediated Hematologic Disorders

Luis E Malpica Castillo, MD, Shannon Palmer, MS, Anqi Zhu, MS, Allison Deal, MS, Sheh-Li Chen, PharmD, Stephan Moll, MD

Blood (2019) 134 (Supplement_1): 792.

https://doi.org/10.1182/blood-2019-121340

Published: 2019

Journal Articles

Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy

Liang Zheng, Di Zhang, Wenjing Cao, Wen-Chao Song, X. Long Zheng

Blood (2019) 134 (13): 1095–1105.

https://doi.org/10.1182/blood.2019001040

Published: 2019

Journal Articles

An Alternative Pathway Specific Flow Cytometric Assay to Detect Complement Activation in Atypical Hemolytic Uremic Syndrome (aHUS)

Jia Yu, Xuan Yuan, MD MSc, Kang Zhou, Daniel White, Samuel A. Merrill, MD PhD, Robert A. Brodsky, MD

Blood (2018) 132 (Supplement 1): 3748.

https://doi.org/10.1182/blood-2018-99-119445

Published: 2018

Journal Articles

Chronic Kidney Disease, Hypertension and Cardiovascular Sequelae during Long Term Follow up of Adults with Atypical Hemolytic Uremic Syndrome

Shruti Chaturvedi, MBBS, MS, Alison R. Moliterno, MD, Samuel A. Merrill, MD PhD, Evan M Braunstein, MD PhD, Xuan Yuan, MD MSc, Christopher John Sperati, MD, Gebran Khneizer, Robert A. Brodsky, MD

Blood (2018) 132 (Supplement 1): 3754.

https://doi.org/10.1182/blood-2018-99-119999

Published: 2018

NARROW

Losing control to bad relatives

Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

Eculizumab and aHUS: to stop or not

Familial risk of developing atypical hemolytic-uremic syndrome

Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome in Pregnancy: A Single Center Retrospective Review

Rare Germline Mutations in Complement Regulatory Genes Make the Antiphospholipid Syndrome Catastrophic

Defibrotide Inhibits Endothelial Cell Injury Induced By Plasmas of Patients with Thrombotic Microangiopathies

Relationship between Pharmacokinetics and Antidrug Antibody Status of ABP 959, a Biosimilar Candidate to Eculizumab: Results from a Pharmacokinetic Similarity Study

Clinical Characteristics of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): A Retrospective Chart Review Study

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Plasmic and Plasic Αre Εxcellent Predictors of Severe ADAMTS13 Deficiency in Thrombotic Microangiopathy Patients without Secondary Causes

Monoclonal Gammopathy with Secondary Atypical Hemolytic-Uremic Syndrome

Treatment of Delayed Hemolytic Transfusion Reactions in Sickle Cell Disease Patients By an Anti-C5 Antibody

Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers

Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab

Adherence to Infectious Disease Screening and Immunization Guidelines When Treating Non-Malignant Immune-Mediated Hematologic Disorders

Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy

An Alternative Pathway Specific Flow Cytometric Assay to Detect Complement Activation in Atypical Hemolytic Uremic Syndrome (aHUS)

Chronic Kidney Disease, Hypertension and Cardiovascular Sequelae during Long Term Follow up of Adults with Atypical Hemolytic Uremic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only